Welcome to our dedicated page for Cellectis SEC filings (Ticker: CLLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Cellectis’s latest 10-K often means navigating hundreds of pages packed with gene-editing science, FDA trial protocols, and complex revenue-sharing notes. If you need to pinpoint when UCART clinical data could trigger milestone payments—or verify cash runway assumptions buried in footnotes—you know the challenge of deciphering this biotech’s disclosures.
Stock Titan solves that problem. Our AI transforms every Cellectis quarterly earnings report 10-Q filing, Cellectis annual report 10-K simplified, and Cellectis 8-K material events explained into concise highlights you can scan in minutes. Want instant alerts on Cellectis insider trading Form 4 transactions? We stream Cellectis Form 4 insider transactions real-time so you can track executive stock moves before markets react. Each filing comes with plain-English summaries, keyword search across sections, and side-by-side comparisons to prior periods—ideal for spotting shifts in R&D spend or partnership economics.
Whether you’re analyzing trial-stage burn rates, monitoring Cellectis proxy statement executive compensation, or seeking a quick Cellectis earnings report filing analysis ahead of a catalyst date, our platform keeps you current. Investors use these insights to:
- Monitor executive stock transactions Form 4
- Compare quarter-over-quarter trial expense trends
- Flag new risk factors in seconds, understanding Cellectis SEC documents with AI
Cellectis S.A. (Nasdaq: CLLS) filed a Form 6-K to disclose outcomes of its 26 June 2025 Combined General Meeting of Shareholders and subsequent Board re-composition. The filing formally incorporates the voting tally (Exhibit 99.1) and the accompanying press release (Exhibit 99.2) into several active U.S. shelf and equity compensation registration statements.
Board and Audit Committee changes: Shareholders elected André Muller to the Board with immediate effect. Concurrently, the mandate of Axel-Sven Malkomes lapsed and the previously announced resignation of Pierre Bastid became effective. Following these departures, the Board re-constituted its Audit Committee, naming Mr. Muller as Chair alongside Donald Bergstrom and Rainer Boehm. The company states that all three members meet both Nasdaq Global Market and SEC Rule 10A-3 independence criteria, ensuring continued compliance with U.S. listing requirements.
No financial statements, operational updates, or transaction details were provided in this submission. The report is limited to corporate governance matters and does not indicate any anticipated impact on Cellectis’ financial performance or strategic direction.
FAQ
What is the current stock price of Cellectis (CLLS)?
What is the market cap of Cellectis (CLLS)?
What does Cellectis specialize in?
How does Cellectis differentiate from competitors?
What are Cellectis’s proprietary technologies?
What challenges does Cellectis face?
What is the significance of allogeneic CAR-T therapies?
What market does Cellectis target?
Who are Cellectis’s main competitors?
What stage of development is Cellectis in?
